CME/CE

Faculty: Tracy Hicks, DNP, MBA Faculty: Melissa Moody, MD Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, parti...

Faculty: Tracy Hicks, DNP, MBA Faculty: Melissa Moody, MD Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, parti...

Faculty: Tracy Hicks, DNP, MBA Faculty: Melissa Moody, MD Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, parti...

Faculty: Tracy Hicks, DNP, MBA Faculty: Melissa Moody, MD Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, parti...

Faculty: Tracy Hicks, DNP, MBA Faculty: Melissa Moody, MD Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, parti...

Faculty: Tracy Hicks, DNP, MBA Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and...

Host: Chadwick R. Johr, MD On-demand webcast with expert insights that untangle the common myths found in Sjögren’s disease by examining its pathophysiology, common signs/symptoms, and latest data on emerging, targeted therapies.

Faculty: Jennifer Goldman, PharmD, CDCES, BC-ADM-FCCP Faculty: Francisco Javier Ampudia-Blasco, MD, PhD Continuous glucose monitoring (CGM) is still recommended for all individuals with diabetes, including those with type 2 diabetes (T2D). Despite this, its use in managing T2D has not been as widespread as expected. New evidence has recently highlighted the benefits of CGM for people with T2D. Joi...

Faculty: Christian Mende, MD, FACP, FACN, FASN, FASH Faculty: Deepak Bhatt, MD, MPH, MBA, FACC, FAHA Recent data from 2024 and 2025 shed light on the prevalence of Cushing syndrome (hypercortisolism) among individuals with hard-to-control metabolic conditions. Now, 2026 brings even more up-to-date insights in this area. Join our expert faculty as they review the latest evidence and discuss its imp...

Faculty: Joseph Kim, MD, MPH, MBA, FACHE Faculty: Samir Dalia, MD Faculty: Christopher Jurief This discussion, led by an expert in quality improvement (QI) implementation, will showcase the outcomes and experiences of clinicians participating in a QI initiative designed to improve the diagnosis, identification, and treatment of patients with HER2-expressing metastatic breast cancer (MBC). Panelist...

Faculty: Adam Brufsky, MD, PhD Dr. Adam Brufsky reviews the clinical role of TROP2-targeted antibody–drug conjugates (ADCs) in hormone receptor–positive (HR+) and metastatic triple-negative breast cancer (TNBC), emphasizing areas of unmet need following CDK4/6 inhibitor progression. He outlines the mechanisms of ADCs and summarizes key phase 3 trial data, highlighting improvements in progression-f...

Faculty: Joseph Kim, MD, MPH, MBA, FACHE Faculty: Samir Dalia, MD Faculty: Christopher Jurief This discussion, led by an expert in quality improvement (QI) implementation, will showcase the outcomes and experiences of clinicians participating in a QI initiative designed to improve the diagnosis, identification, and treatment of patients with HER2-expressing metastatic breast cancer (MBC). Panelist...

Faculty: Enriqueta Felip, MD Faculty: Kristi Orbaugh, MSN, RNP, AOCN This interview-style activity brings together a physician and nurse to explore the scientific rationale and clinical evidence behind subcutaneous (SC) immune checkpoint inhibitors (ICIs) in solid tumors. Through discussion of key clinical trials, they highlight pharmacokinetic equivalence, efficacy, and safety data compared with...

Faculty: Mike Sharma, MD, MSc, FRCPC Faculty: Ashkan Shoamanesh, MD Faculty: Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA Can an antithrombotic meaningfully reduce the risk of recurrent ischemic stroke without increasing major bleeding? Drs. Mike Sharma, Ashkan Shoamanesh, and Brian Mac Grory explore the science behind factor XIa inhibition and its potential to decouple thrombosis from hemostasi...

Faculty: Enriqueta Felip, MD Faculty: Kristi Orbaugh, MSN, RNP, AOCN This interview-style activity brings together a physician and nurse to explore the scientific rationale and clinical evidence behind subcutaneous (SC) immune checkpoint inhibitors (ICIs) in solid tumors. Through discussion of key clinical trials, they highlight pharmacokinetic equivalence, efficacy, and safety data compared with...

Faculty: Mike Sharma, MD, MSc, FRCPC Faculty: Ashkan Shoamanesh, MD Faculty: Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA Can an antithrombotic meaningfully reduce the risk of recurrent ischemic stroke without increasing major bleeding? Drs. Mike Sharma, Ashkan Shoamanesh, and Brian Mac Grory explore the science behind factor XIa inhibition and its potential to decouple thrombosis from hemostasi...

Faculty: Benjamin Levy, MD What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate em...

Faculty: Benjamin Levy, MD Faculty: Melin Khandekar, MD, PhD What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequenc...

Faculty: Benjamin Levy, MD Faculty: Melin Khandekar, MD, PhD What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequenc...

Faculty: Barbara O'Brien, MD Faculty: Nadia Harbeck, MD, PhD What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment se...

Faculty: Barbara O'Brien, MD Faculty: Nadia Harbeck, MD, PhD What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment se...

Faculty: Barbara O'Brien. MD What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will eval...

Host: Carole Bitar, MD, FAAD Guest: Matthew P. Giannetti, MD Guest: Benjamin Ungar, MD On-demand webcast featuring best practices for assessing and diagnosing patients with systemic mastocytosis, the latest data on new and emerging therapies, and strategies for providing patient-centered care.

Host: Sandhya Khurana, MD, FCCP Guest: Syed Shahzad Mustafa, MD Guest: Ashley Wilk, DO, DipABLM Part of the educational program Bridging Specialties ®: Timely Diagnosis and Treatment for Refractory Chronic Cough , this activity examines the diagnostic challenges associated with refractory chronic cough (RCC) and the importance of coordinated, guideline-directed evaluation across specialties. RCC i...

Faculty: Benjamin Levy, MD What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate em...